Research programme: vaccines - VLP Biotech
Alternative Names: Allergy vaccine - VLP Biotech; Alzheimer's disease vaccine - VLP Biotech; Atherosclerosis vaccine - VLP Biotech; Cancer vaccine - VLP Biotech; Hepatitis B viral vaccine- VLP Biotech; Hepatitis C virus vaccine - VLP Biotech; Hypersensitivity vaccine - VLP Biotech; Influenza A virus vaccine - VLP Biotech; Lipid disorder vaccine - VLP Biotech; Malaria vaccine - VLP Biotech; Obesity vaccine - VLP Biotech; palivizumab epitope-displaying VLPs; RSV vaccine - VLP Biotech; VLP 206; VLP-162Latest Information Update: 28 Jul 2023
At a glance
- Originator ChronTech Pharma; Vaccine Research Institute of San Diego
- Developer AstraZeneca; VLP Biotech
- Class Virus-like particle vaccines
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hepatitis B; Malaria; Respiratory syncytial virus infections
Highest Development Phases
- No development reported Anthrax; Hepatitis B; Malaria; Respiratory syncytial virus infections
- Discontinued Alzheimer's disease; Atherosclerosis; Cancer; Hepatitis C; Hypersensitivity; Influenza virus infections; Lipid metabolism disorders; Obesity
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Hepatitis-B in USA
- 28 Jul 2023 No recent reports of development identified for preclinical development in Malaria in USA
- 24 Feb 2021 Preclinical development for Malaria is ongoing in USA